BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22420631)

  • 1. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer.
    Amini A; Lin SH; Wei C; Allen P; Cox JD; Komaki R
    Radiat Oncol; 2012 Mar; 7():33. PubMed ID: 22420631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review.
    Nguyen LN; Komaki R; Allen P; Schea RA; Milas L
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1053-6. PubMed ID: 10421538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy.
    Iocolano M; Wild AT; Hannum M; Zhang Z; Simone CB; Gelblum D; Wu AJ; Rimner A; Shepherd AF
    Acta Oncol; 2020 Feb; 59(2):164-170. PubMed ID: 31608751
    [No Abstract]   [Full Text] [Related]  

  • 4. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
    von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
    Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
    Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of irradiation of inoperable stage III non-small cell lung cancer with 25Gy in five fractions].
    Appold S; Baumann M; Neidt F; Herrmann T
    Strahlenther Onkol; 1999 Jun; 175(6):267-70. PubMed ID: 10392167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.
    Bradley JD; Bae K; Graham MV; Byhardt R; Govindan R; Fowler J; Purdy JA; Michalski JM; Gore E; Choy H
    J Clin Oncol; 2010 May; 28(14):2475-80. PubMed ID: 20368547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
    Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
    Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small-cell lung cancer--impact of total treatment time.
    Nyman J; Bergman B; Mercke C
    Acta Oncol; 1998; 37(6):539-45. PubMed ID: 9860311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.
    Thirion P; Holmberg O; Collins CD; O'Shea C; Moriarty M; Pomeroy M; O'Sullivan C; Buckney S; Armstrong J
    Radiother Oncol; 2004 May; 71(2):163-6. PubMed ID: 15110449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial.
    Iyengar P; Zhang-Velten E; Court L; Westover K; Yan Y; Lin MH; Xiong Z; Patel M; Rivera D; Chang J; Saunders M; Shivnani A; Lee A; Hughes R; Gerber D; Dowell J; Gao A; Heinzerling J; Li Y; Ahn C; Choy H; Timmerman R
    JAMA Oncol; 2021 Oct; 7(10):1497-1505. PubMed ID: 34383006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External beam radiation dose escalation for high grade glioma.
    Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
    Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
    Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status.
    Maguire J; Khan I; McMenemin R; O'Rourke N; McNee S; Kelly V; Peedell C; Snee M
    Eur J Cancer; 2014 Nov; 50(17):2939-49. PubMed ID: 25304298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer.
    Matsuura K; Kimura T; Kashiwado K; Fujita K; Akagi Y; Yuki S; Murakami Y; Wadasaki K; Monzen Y; Ito A; Kagemoto M; Mori M; Ito K; Nagata Y
    Int J Clin Oncol; 2009 Oct; 14(5):408-15. PubMed ID: 19856048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation therapy of stage I and II non-small cell lung cancer (NSCLC).
    Zierhut D; Bettscheider C; Schubert K; van Kampen M; Wannenmacher M
    Lung Cancer; 2001 Dec; 34 Suppl 3():S39-43. PubMed ID: 11740992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
    Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
    Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3 Gy/fraction).
    Valeriani M; Marinelli L; Nicosia L; Reverberi C; De Sanctis V; Mollo D; Osti MF
    Radiol Med; 2019 Dec; 124(12):1324-1332. PubMed ID: 31317381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--mature results for medically inoperable patients.
    Nyman J; Johansson KA; Hultén U
    Lung Cancer; 2006 Jan; 51(1):97-103. PubMed ID: 16213059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.